JP2016516725A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516725A5
JP2016516725A5 JP2016503195A JP2016503195A JP2016516725A5 JP 2016516725 A5 JP2016516725 A5 JP 2016516725A5 JP 2016503195 A JP2016503195 A JP 2016503195A JP 2016503195 A JP2016503195 A JP 2016503195A JP 2016516725 A5 JP2016516725 A5 JP 2016516725A5
Authority
JP
Japan
Prior art keywords
composition
polynucleotide
pro
bax
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503195A
Other languages
English (en)
Japanese (ja)
Other versions
JP6499155B2 (ja
JP2016516725A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029685 external-priority patent/WO2014145042A1/en
Publication of JP2016516725A publication Critical patent/JP2016516725A/ja
Publication of JP2016516725A5 publication Critical patent/JP2016516725A5/ja
Application granted granted Critical
Publication of JP6499155B2 publication Critical patent/JP6499155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503195A 2013-03-15 2014-03-14 自己免疫疾患の治療 Active JP6499155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361800354P 2013-03-15 2013-03-15
US61/800,354 2013-03-15
PCT/US2014/029685 WO2014145042A1 (en) 2013-03-15 2014-03-14 Treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019010717A Division JP2019077715A (ja) 2013-03-15 2019-01-25 自己免疫疾患の治療

Publications (3)

Publication Number Publication Date
JP2016516725A JP2016516725A (ja) 2016-06-09
JP2016516725A5 true JP2016516725A5 (enExample) 2017-04-20
JP6499155B2 JP6499155B2 (ja) 2019-04-10

Family

ID=51537869

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016503195A Active JP6499155B2 (ja) 2013-03-15 2014-03-14 自己免疫疾患の治療
JP2019010717A Pending JP2019077715A (ja) 2013-03-15 2019-01-25 自己免疫疾患の治療
JP2021047124A Pending JP2021091742A (ja) 2013-03-15 2021-03-22 自己免疫疾患の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019010717A Pending JP2019077715A (ja) 2013-03-15 2019-01-25 自己免疫疾患の治療
JP2021047124A Pending JP2021091742A (ja) 2013-03-15 2021-03-22 自己免疫疾患の治療

Country Status (8)

Country Link
EP (1) EP2968606B1 (enExample)
JP (3) JP6499155B2 (enExample)
CN (2) CN105451777A (enExample)
AU (2) AU2014233428B2 (enExample)
CA (1) CA2902565C (enExample)
DK (1) DK2968606T3 (enExample)
ES (1) ES2825078T3 (enExample)
WO (1) WO2014145042A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2758074T3 (da) 2011-09-23 2020-07-27 Univ Loma Linda Bakteriestammer der udtrykker methylasegener og anvendelser deraf
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
CN105451777A (zh) * 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗
WO2016135732A1 (en) * 2015-02-26 2016-09-01 Yeda Research And Development Co. Ltd. Method of promoting hair growth

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
AU686277B2 (en) 1993-11-16 1998-02-05 Pacira Pharmaceuticals, Inc. Vesicles with controlled release of actives
US5549127A (en) 1995-05-03 1996-08-27 Chang; Wen-Hsiung Spring fixing structure for a hairgrip
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
EP0914094A4 (en) 1996-03-28 2000-03-01 Univ Illinois MATERIALS AND METHOD FOR PRODUCING IMPROVED LIPOSOMAL AGENTS
US5851818A (en) 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
US6233483B1 (en) 1997-05-14 2001-05-15 Pacesetter, Inc. System and method for generating a high efficiency biphasic defibrillation waveform for use in an implantable cardioverter/defibrillator (ICD).
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
AU2868200A (en) 1999-02-08 2000-08-25 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
EP1890606A1 (en) * 2005-04-25 2008-02-27 Koninklijke Philips Electronics N.V. Method and apparatus for continuous imaging by ultrasound transducer system
US20090191218A1 (en) * 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
US8778327B2 (en) * 2005-05-11 2014-07-15 Loma Linda University Substances, compositions and methods for preventing and treating immune-mediated inflammatory disorders
WO2009114735A1 (en) * 2008-03-12 2009-09-17 Loma Linda University Dna vaccines and methods for the prevention of transplantation rejection
EP2542698B1 (en) 2010-03-03 2015-04-22 Zymo Research Corporation Detection of dna methylation
DK2758074T3 (da) * 2011-09-23 2020-07-27 Univ Loma Linda Bakteriestammer der udtrykker methylasegener og anvendelser deraf
CN105451777A (zh) * 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗

Similar Documents

Publication Publication Date Title
Merten et al. Viral vectors for gene therapy and gene modification approaches
WO2017077329A3 (en) Nucleic acids, peptides and methods
PH12021551155A1 (en) Recombinant viral vectors and nucleic acids for producing the same
WO2018033254A3 (en) Rna for cancer therapy
MX2021000810A (es) Sistemas y metodos para producir formulaciones de terapia genetica.
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
WO2017191274A3 (en) Rna encoding a therapeutic protein
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
JP2014000092A5 (enExample)
EA201591281A1 (ru) Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
JP2016516725A5 (enExample)
MX2022010959A (es) Terapia genica para trastornos oculares.
JP2018520646A5 (enExample)
TW201613954A (en) Interleukin-10 fusion proteins and uses thereof
RU2016123086A (ru) Способы и композиции для лечения болезни хантингтона
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
NZ629427A (en) Methods and compositions for treating huntington’s disease
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
NZ628385A (en) Batches of recombinant adenovirus with altered terminal ends
WO2020214809A3 (en) Gene therapies for stargardt disease (abca4)
MX2021006253A (es) Terapias génicas para enfermedad neurodegenerativa.
JP2018537089A5 (enExample)
PH12019502442A1 (en) Variants of human bmp7 protein